LOGO
LOGO

$5 And Under

Halozyme Therapeutics Inc. (HALO) Rose Sharply On Pfizer Collaboration

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
rttnewslogo20mar2024

Halozyme Therapeutics Inc. (HALO) announced Friday morning that it has entered into a worldwide Collaboration and License Agreement with Pfizer Inc. (PFE) to develop and commercialize products combining proprietary Pfizer biologics with Halozyme's Enhanze technology.

Halozyme Therapeutics gapped up sharply Friday and climbed throughout the first half of the morning. Shares finished up by 1.49 at $7.01, with volume at over a 4-month high. The stock broke out to a 2 1/2 month high.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Biotech Stocks by Subscribing to RTT Biotech Investor.
Global Economics Weekly Update - Jun 01 - Jun 05, 2026

June 05, 2026 16:18 ET
A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.

Latest Updates on COVID-19